Skip to content

AtriCure ATRC Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Abbott logo
AbbottABT
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
Artivion logo
ArtivionAORT
ITG
Integer HoldingsITGR
Avanos Medical logo
Avanos MedicalAVNS

Other financials

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%
Free cash flow-$7.8M+40.6%

Valuation

See full
Market cap$1.43B-7.9%
Enterprise value$1.36B-11.2%
P/S2.6×-0.6×

Profitability

See full
Gross margin75.6%+0.8pp
Operating margin-5.1%-1.3pp
Net margin-5.6%-1.5pp
FCF margin9.7%

Returns & leverage

See full
Return on equity-6.1%-1.3pp
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Where this comes from

Reported directly by AtriCure in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AtriCure's common stock, shares authorized (in shares)?
AtriCure (ATRC) reported common stock, shares authorized (in shares) of $90M in Q1 2026.
How has AtriCure's common stock, shares authorized (in shares) changed year-over-year?
AtriCure's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $90M to $90M.
What is the long-term trend for AtriCure's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), AtriCure's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $90M to $90M.